Formycon AG (XTER:FYB) Preferred Dividends : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Formycon AG's preferred dividends for the six months ended in Dec. 2024 was €0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Formycon AG Preferred Dividends Historical Data

The historical data trend for Formycon AG's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Preferred Dividends Chart

Formycon AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Preferred Dividends

Get a 7-Day Free Trial

Formycon AG Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Formycon AG Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Formycon AG (XTER:FYB) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Formycon AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

0W4N:UK

Address

Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.formycon.com

Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Executives

Dr. Nicola Mikulcik	Board of Directors
Dr. Stefan Glombitza	Board of Directors
Dr. Carsten Brockmeyer	Board of Directors
Dr. Nicolas Combé	Board of Directors

Formycon AG Headlines

No Headlines